SOLIGENIX, INC. Other General Expense
SOLIGENIX, INC. (SNGX) reported Other General Expense of $5.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherGeneralExpense · last filed 2022-03-29
- SOLIGENIX, INC. other general expense for the quarter ending 2020-12-31 was $0.00.
- SOLIGENIX, INC. other general expense for the quarter ending 2020-09-30 was $0.00.
- SOLIGENIX, INC. other general expense for fiscal 2020 was $5.00M.
| Period end | Other General Expense 3 month | Other General Expense 6 month | Other General Expense 9 month | Other General Expense 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $0.00 derived: sum of 2 quarters · filed 2022-03-29 | $5.00M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $5.00M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $5.00M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |